Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to the company?s previous intimation of 27 March 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
305.8 INR | -1.97% | +2.38% | +22.47% |
May. 16 | India's Biocon posts Q4 profit fall as higher raw material costs bite | RE |
May. 13 | Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
305.8 INR | -1.97% | +2.38% | 4.46B | ||
3.24 RON | +0.62% | +0.62% | 490M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.47% | 4.46B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution